Small Molecule Therapeutics
Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734
Chevaun D. Morrison-Smith, Tatiana M. Knox, Ivona Filic, Kara M. Soroko, Benjamin K. Eschle, Margaret K. Wilkens, Prafulla C. Gokhale, Francis Giles, Andrew Griffin, Bill Brown, Geoffrey I. Shapiro, Beth E. Zucconi, Philip A. Cole, Madeleine E. Lemieux and Christopher A. French
Chevaun D. Morrison-Smith
1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Tatiana M. Knox
1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Ivona Filic
1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Kara M. Soroko
2Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Benjamin K. Eschle
2Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Margaret K. Wilkens
2Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Prafulla C. Gokhale
2Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
Francis Giles
3Developmental Therapeutics Consortium, Chicago, Ilinois.
Andrew Griffin
4Praxis Precision Medicines, Cambridge, Massachusetts.
Bill Brown
5Paraza Pharma Inc., Montreal, Quebec, Canada.
Geoffrey I. Shapiro
6Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Beth E. Zucconi
7Department of Medicine, Division of Genetics, Brigham and Women's Hospital and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
Philip A. Cole
7Department of Medicine, Division of Genetics, Brigham and Women's Hospital and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.
Madeleine E. Lemieux
8Bioinfo, Plantagenet, Ontario, Canada.
Christopher A. French
1Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
DOI: 10.1158/1535-7163.MCT-20-0087 Published July 2020

This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
July 2020
Volume 19, Issue 7
Volume 19, Issue 7
Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734
Chevaun D. Morrison-Smith, Tatiana M. Knox, Ivona Filic, Kara M. Soroko, Benjamin K. Eschle, Margaret K. Wilkens, Prafulla C. Gokhale, Francis Giles, Andrew Griffin, Bill Brown, Geoffrey I. Shapiro, Beth E. Zucconi, Philip A. Cole, Madeleine E. Lemieux and Christopher A. French
Mol Cancer Ther July 1 2020 (19) (7) 1406-1414; DOI: 10.1158/1535-7163.MCT-20-0087
Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734
Chevaun D. Morrison-Smith, Tatiana M. Knox, Ivona Filic, Kara M. Soroko, Benjamin K. Eschle, Margaret K. Wilkens, Prafulla C. Gokhale, Francis Giles, Andrew Griffin, Bill Brown, Geoffrey I. Shapiro, Beth E. Zucconi, Philip A. Cole, Madeleine E. Lemieux and Christopher A. French
Mol Cancer Ther July 1 2020 (19) (7) 1406-1414; DOI: 10.1158/1535-7163.MCT-20-0087
Jump to section
Advertisement